Absence of heparan sulfate proteoglycans in Lewy bodies and Lewy neurites in Parkinson's disease brains

Jack van Horssen^a, Rob A.I. de Vos^b, Ernst N.H. Jansen Steur^c, Guido David^d, Pieter Wesseling^a, Robert M.W. de Waal^a and Marcel M. Verbeek^{e,*}

^a*Department of Pathology, University Medical Center, Nijmegen, The Netherlands*

^b*Laboratorium Pathologie Oost Nederland, Enschede, The Netherlands*

^c*Department of Neurology, Medisch Spectrum Twente, Enschede, The Netherlands*

^d*The Center for Human Genetics, University of Leuven and Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium*

^e*Department of Neurology, University Medical Center, Nijmegen, The Netherlands*

Abstract. α -Synuclein is the major constituent of Lewy bodies and Lewy neurites in Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Relatively little is known about the exact mechanism of α -synuclein deposition and fibrillization in these α -synucleinopathies. In order to better understand the pathogenesis of α -synucleinopathies it is important to identify molecules that regulate the fibrillization of α -synuclein. Since it has been demonstrated that heparan sulfate proteoglycans (HSPGs) and glycosaminoglycans (GAGs) promote the conversion of non-fibrillar amyloid β -protein (A β) into neurotoxic fibrillar A β in Alzheimer's disease, they might also be involved in α -synuclein aggregation. It was the aim of our study to examine the distribution pattern of these macromolecules in PD brains and the possible association with Lewy bodies and Lewy neurites. Although HSPGs clearly colocalized with senile plaques, we were unable to identify HSPGs or GAGs in Lewy bodies and Lewy neurites and therefore concluded that it is likely that α -synuclein fibrillization and stabilization occurs independently of the presence of HSPGs or GAGs.

Keywords: Lewy body, lewy neurites, parkinson's disease, heparan sulfate proteoglycan, glycosaminoglycan

1. Introduction

The neuropathological diagnosis of both Parkinson's disease (PD) and dementia with Lewy bodies (DLB) relies on identification of intraneuronal Lewy bodies and Lewy neurites [8]. These inclusions occur exclusively in specific types of neurons of select regions of the human nervous system [2,31]. It was demonstrated that α -synuclein is the major constituent of Lewy bod-

ies and Lewy neurites, and that anti- α -synuclein antibodies immunostain Lewy bodies and Lewy neurites in PD and DLB brains [1]. α -Synuclein is also the main component of the glial and neuronal inclusions of multiple system atrophy [13].

α -Synuclein was first isolated and purified from the electric organ of *Torpedo californica* [17]. It was suggested that α -synuclein plays a role in neuronal plasticity because its expression in songbirds increased during learning [10]. In normal functioning neurons, α -synuclein is synthesized in the perikaryon and transported to presynaptic terminals. α -Synuclein is usually localized in synaptic boutons, typically in close proximity of, or bound to synaptic vesicles [17]. The native protein likely plays a role in maintenance and stabi-

*Corresponding author: Marcel M. Verbeek, Department of Neurology, University Medical Center Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. Tel.: +31 2436 15192; Fax: +31 2435 40297; E-mail: M.Verbeek@cukz.umcn.nl.

lization of fully matured synapses [18]. However, its normal localization seems to be disturbed in PD/DLB, where reallocation occurs resulting in accumulation of α -synuclein in the cell body and in more proximal parts of the neurites. Monomeric α -synuclein can form fibrils in solution [10,12]. During this fibrillization process, native unfolded α -synuclein undergoes conformational changes resulting in partially folded intermediates and toxic protofibrils. It has been reported that heparan sulfate proteoglycans (HSPGs) and glycosaminoglycans (GAGs) promote the conversion of non-fibrillar A β into neurotoxic fibrillar A β [3,5,23] and may protect A β against proteolytic degradation [5,22]. Furthermore, HSPGs/GAGs have consistently been found in all kinds of amyloid, regardless of the specific type of amyloidogenic protein deposited [23,26–30]. Therefore, it might be expected that these complex macromolecules play a similar role in α -synuclein fibrillogenesis and stabilization. It was the aim of our study to examine the distribution pattern of HSPGs and GAGs in PD brains in order to collect evidence for a specific *in vivo* association of HSPGs/GAGs with α -synuclein.

2. Materials and methods

2.1. Autopsy material

Brain tissue from patients with clinically diagnosed and neuropathologically confirmed PD (with or without dementia) was obtained at autopsy. All brains displayed the presence of α -synuclein-immunoreactive Lewy bodies and Lewy neurites, while at the same time being free of intracytoplasmic inclusions related to non-PD α -synucleinopathies. After the routine autopsy procedure, tissue samples from the anterior cingulate cortex were obtained and snap frozen in liquid nitrogen. Cingulate cortex sections of 10 PD patients (7 male, 3 female) were investigated for the presence of HSPGs and GAGs (age 74.8 ± 7.9 years; post mortem delay 20.1 ± 4.2 hours). This study was conducted with due regard for the restrictions of the Dutch legislation on the use of human tissue material for research purposes (informed consent was obtained of a legal representative of the patient). Samples were anonymized leaving only clinical data accessible.

2.2. Antibodies

Mouse monoclonal antibody synuclein Ab-2 (syn211, NeoMarkers, Fremont, CA), a highly spe-

cific mAb for α -synuclein that does not cross-react with β - and γ -synuclein, was used as primary antibody. Polyclonal antibody 40-4, directed against A β (generous gift of Dr. W.E. van Nostrand, Stony Brook, NY [7]) was used to demonstrate the presence of senile plaques. Additionally, specific antibodies directed against heparinase-digested HSPGs (3G10), heparan sulfate side-chains (JM13, JM403), agrin core protein (JM72) and glypican-1 core protein (S1) were used to study the expression of these molecules in PD brains. The characterization of these antibodies has been described in previous reports [6,24]. Anti-glypican-1 (S1) and anti-agrin (JM72) antibodies were selected because both mAbs strongly stain a variety of amyloidogenic lesions such as neurofibrillary tangles, senile plaques and amyloid-laden vessels. We used biotin-labeled horse anti-mouse as secondary antibody with the exception of primary incubations with JM13 and JM403, in which case biotin-labeled goat anti-mouse IgM was used. All secondary antibodies and the avidin-biotin-peroxidase complex (ABC) were obtained from Vector (Burlingame, CA).

2.3. Immunohistochemistry

For immunohistochemical double-staining, 4 μ m cryosections were air-dried, fixed in acetone for 5 minutes, subsequently for 5 minutes in acetone containing 0.15% H₂O₂ to block endogenous peroxidase activity, and preincubated for 30 minutes with 20% normal horse serum with the exception of staining with JM13 and JM403 in which case we used 20% normal goat serum. Sections were incubated overnight at 4°C with either 3G10, JM13, JM403, S1 or JM72 at concentrations of 10 μ g/ml. In case of staining with 3G10, sections were pretreated with 50 mU heparitinase (heparinase III, EC 4.2.2.8; Sigma Chemical Co., St Louis, MO) diluted in 10 mM HEPES and 2 mM CaCl₂ (pH 7.0) at 37°C for 1 hour. Subsequently, sections were incubated with either biotin-labeled horse anti-mouse antibody in case of primary staining with 3G10, JM72 and S1 or biotin-labeled goat anti-mouse IgM in case of primary staining with JM13 and JM403, for 30 minutes at room temperature and with avidin-labeled Texas Red for 45 minutes. Between incubation steps, sections were thoroughly washed with phosphate buffered saline (PBS). After the last rinse in PBS, sections were first incubated with a mixture of rabbit anti-mouse alkaline phosphatase and rabbit anti-mouse horse radish peroxidase for 30 minutes (dilution 1:20), to block residual free binding sites on the mouse antibodies from the

Fig. 1. Immunofluorescence staining of Lewy bodies, Lewy neurites and senile plaques in sections from PD brains for α -synuclein (mAb Ab-2, green) (A, B), HSPG core protein (3G10, red) (A and D), HSGAG (JM403, red) (B) and A β (pAb 40-4, green) (C). In A nuclei were stained blue. Cortical Lewy bodies and Lewy neurites are stained by the anti- α -synuclein antibody. Both 3G10 and JM403 strongly stained the cerebral (micro)vasculature. Neither HSPG core-protein nor HSGAGs colocalized with α -synuclein (A, B), whereas HSPG core-protein was present in A β -positive senile plaques (E). Original magnification 630 $\times$.

first cycle. The success of this blocking procedure was verified by omitting secondary antibodies from the first cycle. Then, sections were washed with PBS and incubated with either anti- α -synuclein Ab-2 or anti-A β 40-4 at a concentration of 10 μ g/ml. Finally, sections were incubated with FITC-labeled sheep anti-mouse or swine anti-rabbit antibodies, respectively, for one hour at room temperature. Selected sections were also incubated with ToPro-3 for nuclear staining (dilution 1:1000, Molecular probes). Between incubation steps, sections were thoroughly washed with PBS and finally mounted in Vectashield (Vector, Burlingame, CA). All antibodies were diluted in PBS containing 0.1% bovine

serum albumin, which also served as a negative control. Sections were examined using a confocal laser-scanning microscope (Leica, Wetzlar, Germany).

3. Results

Ab-2, a monoclonal antibody directed against α -synuclein, clearly stained Lewy bodies and Lewy neurites throughout the cingulate cortex (Fig. 1A and B). Antibodies directed against HS side-chains (JM13, JM403) and heparinase-digested HSPGs (3G10) in-

tensely stained both parenchymal and leptomeningeal vessels. However, no colocalization with α -synuclein in Lewy bodies and Lewy neurites was observed (Fig. 1A and B). Senile plaques were observed in only one PD patient using anti-A β antibody 40-4 (Fig. 1(C)). In contrast to the absence of HSPGs and GAGs in Lewy bodies and Lewy neurites, senile plaques were clearly decorated with both JM 403 (data not shown) and 3G10 (Fig. 1D and E). Anti-glypican-1 (S1) and anti-agrin (JM72) antibodies did not stain Lewy bodies or Lewy neurites (data not shown). However, JM 72 clearly stained the basement membranes of cerebral vessels, indicating that the absence of Lewy bodies and Lewy neurites staining was not due to technical problems.

4. Discussion

Both Lewy bodies and neurofibrillary tangles are associated with cytoskeletal changes leading to accumulation of altered or misfolded proteins. Lewy bodies and Lewy neurites are characterized by inclusions of aggregated α -synuclein, whereas neurofibrillary tangles and dystrophic neurites are composed of microtubule-associated tau protein. Several studies demonstrated that heparan sulfate proteoglycans and heparan sulfate are present in both senile plaques and tangles, promote A β aggregation *in vitro*, and are involved in the stabilization of these amyloid deposits by providing protection against proteolytic degradation and subsequent removal [14,15,19,23,30]. A large number of components, also observed in association with senile plaques, including ubiquitin, neurofilaments and α B-crystallin have been identified in Lewy bodies. It is unclear, however, if this is a passive association or if these proteins affect α -synuclein fibrillogenesis. It has been described that some pesticides and metals may accelerate the rate of formation of α -synuclein fibrils *in vitro* [24]. Recently, it was found that tissue transglutaminase, by cross-linking α -synuclein, contributed to the generation of α -synuclein aggregates [16].

Relatively little is known about the role of heparan sulfate proteoglycans in α -synuclein fibrillogenesis [21]. Recently, Cohlberg and colleagues demonstrated that glycosaminoglycans, in particular heparan sulfate, heparin and other highly sulfated components, stimulated the formation of α -synuclein fibrils *in vitro* [4]. Apart from its catalytic function, heparin was also incorporated into the fibrils. Based on the binding of basic fibroblast growth factor to hepari-

nase sensitive sites in Lewy bodies, it was suggested that Parkinson disease-associated Lewy bodies contain heparan sulfate proteoglycans [19]. Additionally, several chondroitin sulfate proteoglycan subtypes accumulated in Lewy bodies [9]. We were unable to confirm the accumulation of heparan sulfate proteoglycans/glycosaminoglycans in Lewy bodies and Lewy neurites, suggesting that these sulfated molecules, in contrast to their role in AD pathology, are not involved in α -synuclein fibrillization and stabilization, suggesting that the binding of basic fibroblast growth factor to Lewy bodies may be based on a different type of interaction than the binding to heparan sulfate proteoglycans. In line with our previous observations that heparan sulfate proteoglycans are observed in senile plaques in AD brains (reviewed in [29]), we demonstrated that heparan sulfate proteoglycans and heparan sulfate colocalized with extracellular A β in senile plaques in PD brains. Furthermore, we previously have demonstrated that heparan sulfate proteoglycans accumulate in intracellular tangles [30]. Given the absence of heparan sulfate proteoglycans in Lewy bodies, the present study suggests that heparan sulfate proteoglycans are not always associated with any type of intracellular protein aggregation. In this respect, the pathogenesis of α -synuclein aggregation seems to differ from that of tau aggregation.

Although we cannot exclude that heparan sulfate proteoglycans and heparan sulfate are involved in early stages of Lewy bodies formation, such an involvement was not observed in post-mortem material as a clear colocalization, indicating that either Lewy body formation is independent of the presence of heparan sulfate proteoglycans and heparan sulfate, or that the early stages of Lewy body formation are not represented in our material. Therefore, future research, e.g. using animal models, is warranted to provide more insight into the exact mechanism of α -synuclein fibrillization and a possible role of heparan sulfate proteoglycans and glycosaminoglycans.

Acknowledgements

Financial support was obtained by the "Internationale Stichting Alzheimer Onderzoek" grant number: 98501 and the "Hersenstichting Nederland".

References

- [1] M. Baba, S. Nakajo, P.H. Tu, T. Tomita, K. Nakaya, V.M. Lee, J.Q. Trojanowski and T. Iwatsubo, Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies, *Am. J. Pathol.* **152** (1998), 879–884.
- [2] H. Braak, K. Del Tredici, U. Rub, R.A. De Vos, E.N. Jansen Steur and E. Braak, Staging of brain pathology related to sporadic Parkinson's disease, *Neurobiol. Aging* **24** (2003), 197–211.
- [3] G.M. Castillo, C. Ngo, J. Cummings, T.N. Wight and A.D. Snow, Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability, *J. Neurochem.* **69** (1997), 2452–2465.
- [4] J.A. Cohlberg, J. Li, V.N. Uversky and A.L. Fink, Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein *in vitro*, *Biochemistry* **41** (2002), 1502–1511.
- [5] S.L. Cotman, W. Halfter and G.J. Cole, Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain, *Mol. Cell. Neurosci.* **15** (2000), 183–198.
- [6] H. de-Boeck, V. Lories, G. David, J.J. Cassiman and H. Vanden-Berghe, Identification of a 64 kd heparan sulphate proteoglycan core protein from human lung fibroblast plasma membranes with a monoclonal antibody, *Biochem. J.* **247** (1987), 765–771.
- [7] J. Davis-Salinas, S.M. Saporito-Irwin, F.M. Donovan, D.D. Cunningham and W.E. Van Nostrand, Thrombin receptor activation induces secretion and nonamyloidogenic processing of amyloid β -protein precursor, *J. Biol. Chem.* **269** (1994), 22623–22627.
- [8] K. Del Tredici, U. Rub, R.A. De Vos, J.R. Bohl and H. Braak, Where does parkinson disease pathology begin in the brain? *J. Neuropathol. Exp. Neurol.* **61** (2002), 413–426.
- [9] D.A. DeWitt, P.L. Richey, D. Praprotnik, J. Silver and G. Perry, Chondroitin sulfate proteoglycans are a common component of neuronal inclusions and astrocytic reaction in neurodegenerative diseases, *Brain Res* **656** (1994), 205–209.
- [10] J.E. Duda, V.M. Lee and J.Q. Trojanowski, Neuropathology of synuclein aggregates, *J. Neurosci. Res.* **61** (2000), 121–127.
- [11] J.M. George, H. Jin, W.S. Woods and D.F. Clayton, Characterization of a novel protein regulated during the critical period for song learning in the zebra finch, *Neuron* **15** (1995), 361–372.
- [12] M. Goedert, Alpha-synuclein and neurodegenerative diseases, *Nat. Rev. Neurosci.* **2** (2001), 492–501.
- [13] M. Goedert and M.G. Spillantini, Lewy body diseases and multiple system atrophy as alpha-synucleinopathies, *Mol. Psychiatry* **3** (1998), 462–465.
- [14] M. Hasegawa, R.A. Crowther, R. Jakes and M. Goedert, Alzheimer-like changes in microtubule-associated protein Tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation, *J. Biol. Chem.* **272** (1997), 33118–33124.
- [15] F. Hernandez, M. Perez, J.J. Lucas and J. Avila, Sulfo-glycosaminoglycan content affects PHF-tau solubility and allows the identification of different types of PHFs, *Brain Res* **935** (2002), 65–72.
- [16] E. Junn, R.D. Ronchetti, M.M. Quezado, S.Y. Kim and M.M. Mouradian, Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies, *Proc. Natl. Acad. Sci. USA.* **100** (2003), 2047–2052.
- [17] L. Maroteaux, J.T. Campanelli and R.H. Scheller, Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal, *J. Neurosci.* **8** (1988), 2804–2815.
- [18] D.D. Murphy, S.M. Rueter, J.Q. Trojanowski and V.M. Lee, Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons, *J. Neurosci.* **20** (2000), 3214–3220.
- [19] G. Perry, P. Richey, S.L. Siedlak, P. Galloway, M. Kawai and P. Cras, Basic fibroblast growth factor binds to filamentous inclusions of neurodegenerative diseases, *Brain Res* **579** (1992), 350–352.
- [20] G. Perry, S.L. Siedlak, P. Richey, M. Kawai, P. Cras, R.N. Kalara, P.G. Galloway, J.M. Scardina, B. Cordell, B.D. Greenberg et al, Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer's disease, *J. Neurosci.* **11** (1991), 3679–3683.
- [21] M.S. Pollanen, D.W. Dickson and C. Bergeron, Pathology and biology of the Lewy body, *J. Neuropathol. Exp. Neurol.* **52** (1993), 183–191.
- [22] A.D. Snow, R. Sekiguchi, D. Nochlin, P. Fraser, K. Kimata, A. Mizutani, M. Arai, W.A. Schreier and D.G. Morgan, An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar Abeta-amyloid in rat brain, *Neuron* **12** (1994), 219–234.
- [23] A.D. Snow and T.N. Wight, Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses, *Neurobiol. Aging* **10** (1989), 481–497.
- [24] V.N. Uversky, J. Li, K. Bower and A.L. Fink, Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease, *Neurotoxicology* **23** (2002), 527–536.
- [25] J. van-den-Born, L.P. Van-den-Heuvel, M.A. Bakker, J.H. Veerkamp, K.J. Assmann and J.H. Berden, Monoclonal antibodies against the protein core and glycosaminoglycan side chain of glomerular basement membrane heparan sulfate proteoglycan: characterization and immunohistological application in human tissues, *J. Histochem. Cytochem.* **42** (1994), 89–102.
- [26] J. van Horssen, J. Kleinnijenhuis, C.N. Maass, A.A. Rensink, I. Otte-Höller, G. David, L.P. van den Heuvel, P. Wesseling, R.M. de Waal and M.M. Verbeek, Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques, *Neurobiol. Aging* **23** (2002), 537–545.
- [27] J. van Horssen, I. Otte-Höller, G. David, M.L. Maat-Schieman, L.P. van den Heuvel, P. Wesseling, R.M. de Waal and M.M. Verbeek, Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains, *Acta Neuropathol. (Berl.)* **102** (2001), 604–614.
- [28] J. van Horssen, M.M. Wilhelmus, R. Heljasvaara, T. Pihlajaniemi, P. Wesseling, R.M. de Waal and M.M. Verbeek, Collagen XVIII: a novel heparan sulfate proteoglycan associated with vascular amyloid depositions and senile plaques in Alzheimer's disease brains, *Brain Pathol* **12** (2002), 456–462.
- [29] J. van Horssen, P. Wesseling, L.P. van den Heuvel, R.M. de Waal and M.M. Verbeek, Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders, *Lancet Neurol* **2** (2003), 482–492.
- [30] M.M. Verbeek, I. Otte-Höller, J. van den Born, L.P. van den Heuvel, G. David, P. Wesseling and de R.M. Waal,

Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain, *Am. J. Pathol.* **155** (1999), 2115–2125.

[31] R.A. de Vos, E.N. Jansen, F.C. Stam, R. Ravid and D.F. Swaab,

Lewy body disease: clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia, *Clin Neurol Neurosurg* **97** (1995), 13–22.